TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Bioxyne Limited ( (AU:BXN) ) has shared an update.
Bioxyne Limited has appointed Mr. Paul Mitchell as the Chief Financial Officer of its subsidiary, Breathe Life Sciences, to enhance its financial leadership amid rapid growth. Mr. Mitchell’s extensive experience in strategic planning and pharmaceutical manufacturing will support the company’s expansion in manufacturing and distributing controlled medicines, including medicinal cannabis, psilocybin, and MDMA, across Australia and the UK, aligning with Bioxyne’s ambitious international strategy.
The most recent analyst rating on (AU:BXN) stock is a Buy with a A$0.04 price target. To see the full list of analyst forecasts on Bioxyne Limited stock, see the AU:BXN Stock Forecast page.
More about Bioxyne Limited
Bioxyne Limited is an Australian pharmaceutical company that focuses on the development and commercialization of innovative medicines and active pharmaceutical ingredients. Through its subsidiary, Breathe Life Sciences, the company is expanding into the production of psychedelic compounds for therapeutic use. Breathe Life Sciences is a GMP-licensed manufacturer and distributor of controlled substances, including medicinal cannabis, psilocybin, and MDMA, with operations in Australia, the UK, Europe, and Japan.
Average Trading Volume: 3,170,216
Technical Sentiment Signal: Buy
Current Market Cap: A$81.02M
Find detailed analytics on BXN stock on TipRanks’ Stock Analysis page.